[{"orgOrder":0,"company":"University of North Carolina","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase I","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of North Carolina \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"University of North Carolina \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Parexel"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"IRELAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Undisclosed","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Mallinckrodt Pharmaceuticals | Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Mallinckrodt Pharmaceuticals | Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Mallinckrodt Pharmaceuticals | Takeda Pharmaceutical"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Sucampo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Sucampo Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Sucampo Pharmaceuticals"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Mallinckrodt Pharmaceuticals | Sucampo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Mallinckrodt Pharmaceuticals | Sucampo Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Mallinckrodt Pharmaceuticals | Sucampo Pharmaceuticals"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Takeda Pharmaceutical | Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"IRELAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Takeda Pharmaceutical | Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Takeda Pharmaceutical | Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"University of South Alabama","sponsor":"Takeda Pharmaceutical | Sucampo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of South Alabama","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of South Alabama \/ Takeda Pharmaceutical | Sucampo Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"University of South Alabama \/ Takeda Pharmaceutical | Sucampo Pharmaceuticals"},{"orgOrder":0,"company":"Augusta University","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Augusta University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Augusta University \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Augusta University \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"University of Michigan","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Michigan","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Michigan \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"University of Michigan \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Dartmouth-Hitchcock Medical Center","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Dartmouth-Hitchcock Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dartmouth-Hitchcock Medical Center \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Dartmouth-Hitchcock Medical Center \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"University of Rochester","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Neurology","graph2":"Phase IV","graph3":"University of Rochester","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Rochester \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"University of Rochester \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Texas Tech University Health Sciences Center, El Paso","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Texas Tech University Health Sciences Center, El Paso","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Texas Tech University Health Sciences Center, El Paso \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Texas Tech University Health Sciences Center, El Paso \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Par Pharmaceutical","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Par Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Par Pharmaceutical \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"10","companyTruncated":"Par Pharmaceutical \/ Novum Pharmaceutical Research Services"},{"orgOrder":0,"company":"Cedars-Sinai","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Lubiprostone","moa":"Chloride channel protein 2","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Cedars-Sinai","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cedars-Sinai \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Cedars-Sinai \/ Takeda Pharmaceutical"}]
Find Clinical Drug Pipeline Developments & Deals for Lubiprostone
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
